Leukemia & Lymphoma Society | Discovery Grant Program
Event details
| Date | 18.09.2024 |
| Category | Call for proposal |
Aim: The Leukemia & Lymphoma Society, Inc. (LLS) funds research on leukemia, lymphoma, myeloma, and all other rare blood cancers. The LLS aims at funding the best science to bring better treatments to patients with every form of blood cancer.
The Discovery Grant Program (DGP) is a research award program designed to encourage basic research, technological innovation, and informatics pipeline development. It aims at supporting cutting edge, innovative research that is discovery oriented, concerned with understanding blood cancer properties and vulnerabilities and aimed toward advancing treatments for blood cancers.
Examples of projects of potential interest include:
Duration: 3 years
Eligibility: The program welcomes applications from US citizens and non-US citizens, as well as applicants who are performing research outside the United States. Applicants must hold a PhD, MD, DVM, or equivalent degree. Applicants must be independent investigators affiliated with a non-profit institution at the time funding commences and for the duration of the award. Further, they must be established investigators, defined as having more than 3 years in an independent faculty appointment at the time of the Letter of Intent.
How to Apply: The 2-stage application process begins with a Letter of Intent, to be submitted on the LLS Research Portal (create account here). LOIs should provide brief descriptions of how the goals and/or approaches are novel and innovative, and what impact the research may have on blood cancer. All LOIs will be reviewed for eligibility, relevance and responsiveness to the goals of the program. Those judged to be the most promising will be invited to submit a full application. At the full application stage, an Institutional signature is required; please contact the Research Office for this step.
Deadline: Letter of Intent: 18 September, 2024. 3pm ET
Notification of full application invite: January 2025
Full Application: 03 March 2025 (3PM ET)
Award start: 01 October 2025
Further information
The Discovery Grant Program (DGP) is a research award program designed to encourage basic research, technological innovation, and informatics pipeline development. It aims at supporting cutting edge, innovative research that is discovery oriented, concerned with understanding blood cancer properties and vulnerabilities and aimed toward advancing treatments for blood cancers.
Examples of projects of potential interest include:
- cellular activities that underlie the behavior and vulnerabilities of blood cancer cells including phenomena or processes such as clonal evolution, autophagy, unique metabolic vulnerabilities, inflammation/inflammasomes, DNA damage responses, organellar changes, and poorly understood cellular regulatory mechanisms
- resistance mechanisms including immune evasion, resistant clone evolution and cellular changes underlying development of resistance to chemotherapies
- novel biomarkers or techniques to detect and monitor blood cancer development and progression
- blood cancer cell interactions with the microenvironment and with the immune system, including exploration of novel immune synapses
- clinical trials or correlative studies associated with clinical trials
- development of a drug or treatment that already has shown proof of concept
- research that is primarily confirmatory or minimally incremental
- research into cellular behavior, mechanisms or development not in the context of blood cancer
- studies of normal hematopoiesis
Duration: 3 years
Eligibility: The program welcomes applications from US citizens and non-US citizens, as well as applicants who are performing research outside the United States. Applicants must hold a PhD, MD, DVM, or equivalent degree. Applicants must be independent investigators affiliated with a non-profit institution at the time funding commences and for the duration of the award. Further, they must be established investigators, defined as having more than 3 years in an independent faculty appointment at the time of the Letter of Intent.
How to Apply: The 2-stage application process begins with a Letter of Intent, to be submitted on the LLS Research Portal (create account here). LOIs should provide brief descriptions of how the goals and/or approaches are novel and innovative, and what impact the research may have on blood cancer. All LOIs will be reviewed for eligibility, relevance and responsiveness to the goals of the program. Those judged to be the most promising will be invited to submit a full application. At the full application stage, an Institutional signature is required; please contact the Research Office for this step.
Deadline: Letter of Intent: 18 September, 2024. 3pm ET
Notification of full application invite: January 2025
Full Application: 03 March 2025 (3PM ET)
Award start: 01 October 2025
Further information
- More information about the program, guidelines, and instructions are available here
- The application portal can be found here
- For any other questions, please contact the Research Office
Practical information
- General public
- Free